Innovative Gel Developed in Sydney
Phebra, an Australian-based specialty pharmaceutical company, has launched Laceraine, a novel anaesthetic wound gel designed and manufactured in Australia. Available from 7 April 2026, this development underscores Phebra’s commitment to enhancing Australia’s capability in producing essential medicines.
Laceraine combines lidocaine, tetracaine, and adrenaline to provide localised anaesthesia for open lacerations. It is crucial in settings such as hospital emergency departments, general practices, urgent care clinics, and other frontline health settings across the community.
Phebra’s Chief Executive Officer, Andre Vlok, said, “We’re extremely proud to be adding Laceraine to Phebra’s portfolio of Australian-made medicines to address an unmet need for healthcare professionals and their patients.”
The gel formulation of Laceraine offers essential pain relief during wound cleaning and closure, especially important for patients, particularly children. Conceived and developed by Phebra’s Co-Founder, the late Dr. Mal Eutick, it is manufactured in Lane Cove West, Sydney.
Benefits and Availability
Laceraine was developed with support from Australian clinicians and offers numerous benefits. It reduces treatment time in emergency departments, minimises bleeding, and lowers the risk of needlestick injuries for healthcare professionals. This supports a safer and more efficient medical environment.
Andre Vlok added, “Laceraine delivers multiple benefits – it’s less painful, reduces bleeding, treatment time in the emergency department, and the risk of needlestick injuries for healthcare professionals.”
Laceraine is now available through Phebra’s national distribution network, ensuring healthcare facilities across Australia have access to this essential product. Its availability provides rapid and effective pain relief for patients with superficial open lacerations.
Phebra, founded in 1993, focuses on creating critical medicines that save and improve lives. The company aims to strengthen Australia’s healthcare sector by offering innovative solutions. For more detailed information about Laceraine, healthcare professionals and interested parties are encouraged to visit Phebra’s official website.
Last updated: 7 April 2026, 3:04 pm
